Phase 1 Study of Safety, Tolerability, and Pharmacokinetics of PTC299, an Inhibitor of Stress‐Regulated Protein Translation

PTC299 is a novel small molecule that specifically blocks the production of protein from selected mRNAs that under certain conditions use noncanonical ribosomal translational pathways. Hypoxia, oncogenic transformation, and viral infections limit normal translation and turn on these noncanonical tra...

Full beskrivning

Sparad:
Bibliografiska uppgifter
I publikationen:Clin Pharmacol Drug Dev
Huvudupphovsmän: Weetall, Marla, Davis, Thomas, Elfring, Gary, Northcutt, Valerie, Cao, Liangxian, Moon, Young‐Choon, Riebling, Peter, Dali, Mandar, Hirawat, Samit, Babiak, John, Colacino, Joseph, Almstead, Neil, Spiegel, Robert, Peltz, Stuart W.
Materialtyp: Artigo
Språk:Inglês
Publicerad: John Wiley and Sons Inc. 2016
Ämnen:
Articles
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC5066743/
https://ncbi.nlm.nih.gov/pubmed/27310330
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cpdd.240
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk